台灣神隆股份有限公司
- 主成分
- Exemestane contains not less than 98.0 percent and not more than 102.0 percent of C20H24O2 calculated on the anhydrous basis.
- 適應症
- 抗乳癌藥。
- 主成分
- Regadenoson contains not less than 98.0 percent and not more than 102.0 percent of C15H18N8O5‧H2O
- 適應症
- 放射性心肌灌注顯像劑。
- 主成分
- Decitabine contains not less than 98.0 percent and not more than 102.0 percent of C8H12N4O4 calculated on the dried basis.
- 適應症
- 適用於治療65歲(含)以上且不適合進行標準誘導化學療法之新診斷出患有原發性或續發性急性骨髓性白血病病患﹝AML，依據世界衛生組織(WHO)分類﹞須符合Poor-or intermediate-risk Cytogenetics，且不適合用於﹝Acute Promyelocytic Leukemia (M3 Classification)﹞。
- 主成分
- Travoprost contains not less than 96.0 % and not more than 102.0 % of C26H35F3O6 calculated on the anhydrous and solvent free basis.
- 適應症
- 治療青光眼及降低眼壓。
- 主成分
- Bimatoprost contains not less than 98.0 percent and not more than 102.0 percent of C25H37NO4 calculated on the anhydrous and solvent free basis.
- 適應症
- 治療青光眼及降低眼壓。
- 主成分
- Desmopressin acetate contains not less than 95.0 percent and not more than 105.0 percent of C48H68N14O14S2.
- 適應症
- 中樞性尿崩症(diabetes insipidus)、原發性夜尿症(noctumal enuresis)、輕度A型血友病(Hemophilia A)、Type I von Willebrand disease。
- 主成分
- Azacitidine contains not less than 98.0 percent and not more than 102.0 percent of C8H12N4O5 calculated on the anhydrous and solvent-free basis.
- 適應症
- 治療骨髓發育不良症候群。
- 主成分
- Modafinil contains not less than 98.0 percent and not more than 101.5 percent of C15H15NO2S, calculated on the dried basis.
- 適應症
- 提神藥 (Wakefulness-Promoting Agent)。
- 主成分
- Topiramate contains not less than 98.0 percent and not more than 102.0 percent of C12H21NO8S, calculated on the dried basis.
- 適應症
- 抗癲癇藥(Antiepilepsy)。
- 主成分
- Paclitaxel (2nd) contains not less than 97.0 percent and not more than 102.0 percent of C47H51NO14 calculated on the anhydrous basis.
- 適應症
- 抗腫瘤用藥/ 有絲分裂抑制劑。
- 主成分
- Leuprolide Mesylate contains not less than 97.0 percent and not more than 103.0 percent of C59H84N16O12•(CH4O3S)n，n=1.5 to 1.8 calculated on anhydrous and methanesulfonic acid-free basis.
- 適應症
- 抗腫瘤劑。
- 主成分
- EFLORNITHINE HYDROCHLORIDE
- 適應症
- 非洲睡眠症(AFRICAN SLEEPING SICKNESS)。
- 主成分
- Pemetrexed Disodium contains not less than 97.5 percent and not more than 102.0 percent of C20H19N5Na2O6 calculated on the anhydrous and solvent-free basis.
- 適應症
- 抗腫瘤用藥/代謝拮抗劑。
- 主成分
- Pemetrexed Disodium contains not less than 97.5 percent and not more than 102.0 percent of C20H19N5Na2O6 calculated on the anhydrous and solvent-free basis.
- 適應症
- 抗腫瘤用藥/代謝拮抗劑。
- 主成分
- Docetaxel contains not less than 97.5 percent and not more than 102.0 percent of C43H53NO14 calculated on the solvent-free and anhydrous basis.
- 適應症
- 乳癌、非小細胞肺癌、前列腺癌、胃腺癌、頭頸癌。
- 主成分
- Fulvestrant contains not less than 97.0 percent and not more than 102.0 percent of C32H47F5O3S calculated on the anhydrous basis.
- 適應症
- 抗雌激素療法。
- 主成分
- Galantamine Hydrobromide contains not less than 98.0 percent and not more than 102.0 percent of C17H21NO3.HBr calculated on the dried basis.
- 適應症
- 阿茲海默氏症(Alzheimer's Disease)
- 主成分
- Letrozole contains not less than 98.0 percent and not more than 102.0 percent of C17H11N5 calculated on the dried basis.
- 適應症
- 轉移性乳癌。
- 主成分
- Elagolix Sodium contains not less than 98 percent and not more than 102.0 percent of C32H29F5N3O5Na.
- 適應症
- 緩解子宮內膜異位引起的中重度疼痛。
- 主成分
- Tamsulosin hydrochloride contains not less than 98.5 percent and not more than 101.0 percent of C20H28N2O5S？HCl calculated on the dried basis.
- 適應症
- 前列腺肥大症(增生)所伴隨的排尿障礙。
- 主成分
- Irinotecan hydrochloride contains not less than 98.0 percent and not more than 102.0 percent of C33H38N4O6HCl？3H2O calculated on the dried basis.
- 適應症
- 抗癌藥(Antineoplastic)。
- 主成分
- Gemcitabine hydrochloride contains not less than 97.5 percent and not more than 101.5 percent of C9H11F2N3O4. HCl calculated on the dried basis.
- 適應症
- 抗癌藥。
- 主成分
- Docetaxel contains not less than 98.0 percent and not more than 102.0 percent of C43H53NO14 calculated on the as is basis.
- 適應症
- 抗乳癌、非小細胞肺癌、前列腺癌藥物。
- 主成分
- Entecavir monohydrate contains not less than 98.0 percent and not more than 102.0 percent of C12H15N5O3‧H2O calculated on the anhydrous basis.
- 適應症
- 治療有B型肝炎病毒複製跡象的成人慢性B型肝炎患者。
- 主成分
- Bivalirudin contains not less than 95.0 percent and not more than 103.0 percent of C98H138N24O33 calculated on the anhydrous and trifluoroacetic acid free basis.
- 適應症
- 抗凝血劑。
- 主成分
- Zoledronic Acid contains not less than 98.0 percent and not more than 102.0 percent of C5H10N2O7P2‧H2O calculated on the as is basis.
- 適應症
- 與標準癌症治療併用，適用於多發性骨髓瘤及固體腫瘤併有骨骼轉移之病人。用於攝護腺癌病人之骨骼轉移時，應至少接受過一種荷爾蒙治療而仍持續惡化者。治療惡性腫瘤之高血鈣併發性(HCM)。
- 主成分
- Dantrolene Sodium contains not less than 98.0 percent and not more than 102.0 percent of C14H9N4NaO5 3.5H2O.
- 適應症
- 骨骼肌鬆弛劑 Muscle Relaxant (Skeletal)
- 主成分
- Capecitabine contains not less than 98.0 percent and not more than than 102.0 percent of C15H22FN3O6 calculated on the anhydrous and solvent free basis.
- 適應症
- Capecitabine可治療轉移性大腸（結腸直腸）癌病患。Capecitabine可作為第三期結腸癌患者手術後輔助性療法。Capecitabine與Docetaxel併用於治療對Anthracycline化學治療無效之局部晚期或轉移性乳癌病患。Capecitabine亦可單獨用於對紫杉醇（Taxane）及Anthracycline化學治療無效，或無法使用Anthracycline治療之局部晚期或轉移性乳癌病患。Capecitabine合併Platinum可使用於晚期胃癌之第一線治療。
- 主成分
- Anastrozole contains not less than 98.0 percent and not more than 102.0 percent of C17H19N5 calculated on the dried basis.
- 適應症
- 抗腫瘤原料藥。
- 主成分
- Docetaxel trihydrate contains not less than 98.0 percent and not more than 101.0 percent of C43H53NO14？3H2O calculated on the dried basis and acetic acid free.
- 適應症
- 抗癌藥。
- 主成分
- Ondansetron Hydrochloride contains not less than 98.0 percent and not more than 102.0 percent of C18H19N3O‧HCl‧2H2O.
- 適應症
- 治療化學療法和放射性療法引起之嘔吐。
- 主成分
- Flavoxate Hydrochloride contains not less than 98.0 percent and not more than 102.0 percent of C24H25NO4. HCl.
- 適應症
- 因慢性前列腺炎、膀胱炎，所引起之頻尿、排尿困難、神經性之頻尿。
- 主成分
- Riluzole contains not less than 98.0 percent and not more than 102.0 percent of C8H5F3N2OS calculated on the anhydrous basis.
- 適應症
- 肌萎縮脊髓側索硬化症。
- 主成分
- Granisetron Hydrochloride contains not less than 97.0 percent and not more than 102.0 percent of C18H24N4O.HCl calculated on the dried basis.
- 適應症
- 預防及治療抗腫瘤化學療法所引起的噁心、嘔吐及治療抗腫瘤放射線療法引起的噁心、嘔吐。預防全身性及半身性抗腫瘤放射線療法引起的噁心、嘔吐。治療手術後引起的噁心、嘔吐。
- 主成分
- Paclitaxel contains not less than 97.0 percent and not more than 102.0 percent of C47H51NO14.
- 適應症
- 抗癌藥物。
- 主成分
- Topotecan Hydrochloride contains not less than 98.0 percent and not more than 102.0 percent of C23H23N3O5.HCl calculated on the anhydrate basis.
- 適應症
- 卵巢癌及小細胞肺癌之第二線化學治療(第一線化療應包括白金化合物)Hycamtin與cisplatin併用適用於治療經組織學檢查確定患有第IV-B期復發性或持續性子宮頸癌，且不適合以外科手術及(或)放射療法進行治療的患者。
- 主成分
- Cladribine contains not less than 97.0 percent and not more than 102.0 percent of C10H12ClN5O3 calculated on the anhydrous and solvent free basis.
- 適應症
- 復發型多發性硬化症(臨床上有發作，且前兩年有兩次復發者)。
- 主成分
- Fondaparinux Sodium contains not less than 97.0 percent and not more than 103.0 percent of C31H43N3Na10O49S8 calculated on anhydrous basis.
- 適應症
- 預防接受骨科下肢手術（髋骨骨折，膝關節或髋關節置換手術）之靜脈血栓高危險群（曾發生有症狀之靜脈血栓症）患者發生靜脈血栓栓塞事件（VTE）。治療患有不穩定型心絞痛或非ST段升高型心肌梗塞（UA/NSTEMI）且不適合接受緊急（120分鐘內）侵入性治療（PCI）的成人。治療ST段升高型心肌梗塞（STEMI）的急性冠狀症候群，藉以預防使用血栓溶解劑治療或原先即不準備接受任何其它型式之再灌流治療的患者發生死亡和心肌再度梗塞。